Interferon-alpha

• 

  Subject Areas on Research

  • 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. 
  • A Computational Model of Inhibition of HIV-1 by Interferon-Alpha. 
  • A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. 
  • A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma. 
  • A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma. 
  • A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. 
  • A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. 
  • A randomized comparison of two doses of human lymphoblastoid interferon-alpha in hairy cell leukemia. Wellcome HCL Study Group. 
  • A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. 
  • A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. 
  • A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. 
  • Adherence during antiviral treatment regimens for chronic hepatitis C: a qualitative study of patient-reported facilitators and barriers. 
  • Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. 
  • Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. 
  • Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. 
  • Alpha 2-macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism. 
  • An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. 
  • An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. 
  • Analysis of site performance in academic-based and community-based centers in the IDEAL Study. 
  • Antiangiogenic agents protect liver sinusoidal lining cells from cold preservation injury in rat liver transplantation. 
  • Antifibrotic therapies: will we ever get there? 
  • Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo. 
  • Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. 
  • Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma. 
  • Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. 
  • Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. 
  • Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. 
  • Boceprevir for HCV in patients with HIV: where next? 
  • Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. 
  • Boceprevir for untreated chronic HCV genotype 1 infection. 
  • C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. 
  • CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. 
  • CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer. 
  • Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. 
  • Carcinoid tumors of the gastrointestinal tract. A review and the Duke University institutional overview. 
  • Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. 
  • Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. 
  • Chemoimmunotherapy of metastatic malignant melanoma. The Salpétrière Hospital (SOMPS) experience. 
  • Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. 
  • Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. 
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. 
  • Clinical benefits of pegylated proteins in oncology. 
  • Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C. 
  • Clinical uses of pegylated pharmaceuticals in oncology. 
  • Cloned endothelium derived from autoimmune vascular disease retain structural and functional characteristics of normal endothelial cells. 
  • Conjunctival intraepithelial neoplasia. 
  • Cost-effectiveness considerations in the treatment of essential thrombocythemia. 
  • Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. 
  • Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. 
  • Cytokine expression by models of human trophoblast as assessed by a semiquantitative reverse transcription-polymerase chain reaction technique. 
  • DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. 
  • Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. 
  • Definition and management of anemia in patients infected with hepatitis C virus. 
  • Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta. 
  • Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. 
  • Diagnosis and management of conjunctival and corneal intraepithelial neoplasia using ultra high-resolution optical coherence tomography. 
  • Diagnosis and treatment of chronic hepatitis C infection. 
  • Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. 
  • Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. 
  • Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. 
  • Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. 
  • Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. 
  • Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C. 
  • Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. 
  • Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. 
  • Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. 
  • Emerging Roles of Type-I Interferons in Neuroinflammation, Neurological Diseases, and Long-Haul COVID. 
  • Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. 
  • Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. 
  • Fibroblastic rheumatism: a report of 4 cases with potential therapeutic implications. 
  • Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy. 
  • Frailty models with missing covariates. 
  • Future trends in managing hepatitis C. 
  • Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma. 
  • Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. 
  • Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. 
  • Graft-versus-host reactions: anti-leukemia effects of donor T cells. 
  • HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients. 
  • Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. 
  • Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection. 
  • Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. 
  • Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. 
  • Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. 
  • Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. 
  • Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. 
  • Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma. 
  • Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma. 
  • IFN-α inhibits telomerase in human CD8⁺ T cells by both hTERT downregulation and induction of p38 MAPK signaling. 
  • IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. 
  • Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. 
  • Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013. 
  • In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. 
  • Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. 
  • Inducible nitric oxide synthase expression by peritoneal macrophages in endometriosis-associated infertility. 
  • Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study. 
  • Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. 
  • Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. 
  • Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients. 
  • Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo. 
  • Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment. 
  • Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. 
  • Interferon in the treatment of cutaneous T-cell lymphoma. 
  • Interferon lambda protects the female reproductive tract against Zika virus infection. 
  • Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of Alpha Interferon. 
  • Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). 
  • Interferon-inducible mechanism of dendritic cell-mediated HIV-1 dissemination is dependent on Siglec-1/CD169. 
  • Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab. 
  • Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. 
  • JAK2 is required for induction of the murine DUB-1 gene. 
  • Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. 
  • Low interleukin-12 activity in severe Plasmodium falciparum malaria. 
  • Making it happen: managed care considerations in vanquishing hepatitis C. 
  • Management of hepatitis C virus infection: the basics. 
  • Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. 
  • Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. 
  • Mixed model analysis of censored longitudinal data with flexible random-effects density. 
  • Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. 
  • NCCN Practice Guidelines for Chronic Myelogenous Leukemia. 
  • New therapies for chronic hepatitis C virus infection. 
  • Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. 
  • Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation. 
  • Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. 
  • Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. 
  • Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. 
  • Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. 
  • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. 
  • Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients. 
  • Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. 
  • Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia. 
  • Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. 
  • PharmGKB summary: peginterferon-α pathway. 
  • Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. 
  • Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. 
  • Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. 
  • Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer. 
  • Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma. 
  • Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. 
  • Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. 
  • Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma. 
  • Polyribonucleotides induce nitric oxide production by human monocyte-derived macrophages. 
  • Potential nonhormonal therapeutics for medical treatment of leiomyomas. 
  • Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin. 
  • Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance). 
  • Predictors of consent to pharmacogenomics testing in the IDEAL study. 
  • Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. 
  • Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? 
  • Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. 
  • Pure red cell aplasia following pegylated interferon alpha treatment. 
  • Racial differences in hepatitis C treatment eligibility. 
  • Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. 
  • Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. 
  • Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. 
  • Regulation of microglial function by interferons. 
  • Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. 
  • Relative resistance of HIV-1 founder viruses to control by interferon-alpha. 
  • Rendering the leukemia cell susceptible to attack. 
  • Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. 
  • Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? 
  • Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. 
  • Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C. 
  • SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway. 
  • Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. 
  • Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. 
  • Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. 
  • Sarcoidosis induced by interferon therapy. 
  • Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. 
  • Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. 
  • Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. 
  • Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. 
  • Short small-interfering RNAs produce interferon-α-mediated analgesia. 
  • Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. 
  • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. 
  • Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. 
  • Subcutaneous interferon alfa for the treatment of cutaneous pseudolymphoma. 
  • Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). 
  • Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure. 
  • Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity. 
  • Systemic antiviral drugs used in ophthalmology. 
  • Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. 
  • Telaprevir for previously treated chronic HCV infection. 
  • Telaprevir for previously untreated chronic hepatitis C virus infection. 
  • Telaprevir for the treatment of chronic hepatitis C infection. 
  • Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. 
  • The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. 
  • The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA. 
  • The rapid evolution of treatment strategies for hepatitis C. 
  • The role of IFN-alpha and nitric oxide in the release of HMGB1 by RAW 264.7 cells stimulated with polyinosinic-polycytidylic acid or lipopolysaccharide. 
  • Therapy of acute and fulminant hepatitis B. 
  • Transmission of Multiple HIV-1 Subtype C Transmitted/founder Viruses into the Same Recipients Was not Determined by Modest Phenotypic Differences. 
  • Treatment choices in chronic myelogenous leukemia. 
  • Treatment of acute hepatitis C infection: more pieces of the puzzle? 
  • Treatment of acute hepatitis C with interferon alfa-2b. 
  • Treatment of chronic hepatitis C in blacks and non-Hispanic whites. 
  • Treatment of hepatitis C in special populations. 
  • Type I interferon pathway in adult and juvenile dermatomyositis. 
  • Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication. 
  • Variation in interferon sensitivity and induction among strains of eastern equine encephalitis virus. 
  • Vasculitis as a Major Morbidity Factor in Patients With Partial RAG Deficiency. 
  • Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. 
  • Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. 
  • Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. 
  • alpha-Interferon and 5-fluorouracil: possible mechanisms of antitumor action. 
• 

  Keywords of People

  • Choi, Steven Sok, Associate Professor of Medicine, Medicine, Gastroenterology
  • Gunn, Michael Dee, Professor of Medicine, Integrative Immunobiology
  • Shinohara, Mari L., Professor of Integrative Immunobiology, Cell Biology